AstraZeneca

Core earnings for the three months ended June 30 jumped 18% to US$2.63 per share

CSPC is eligible to receive US$30 million as upfront payment and up to US$1.7 billion in additional payments

The investment includes a new building at the British drugmaker’s headquarters in Cambridge

Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion

Its chief executive officer Pascal Soriot has a target of US$80 billion in annual sales by 2030

The deal builds on existing collaboration between the companies in areas such as artificial intelligence

The retailer has recently increased its use of AI across internal operations

The firm will also list its shares on the NYSE to gain access to a deeper capital pool

Profit after tax rose to US$2.45 billion in the three months to the end of June